Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma.

Bachchu Lal Aditya Kulkarni Joseph R McDermott Rana Rais Jesse Alt Ying Wu Hernando Lopez-Bertoni Sophie Sall Umesh Kathad Jianli Zhou Barbara S Slusher Kishor Bhatia John Laterra

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

These results establish LP-184 as a promising chemotherapeutic for GBM with enhanced efficacy in intrinsic or spironolactone-induced TC-NER deficient tumors.

Keyphrases

diabetic rats
stem cells
bone marrow
endothelial cells